[go: up one dir, main page]

ECSP12011844A - 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo - Google Patents

2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo

Info

Publication number
ECSP12011844A
ECSP12011844A ECSP12011844A ECSP12011844A EC SP12011844 A ECSP12011844 A EC SP12011844A EC SP12011844 A ECSP12011844 A EC SP12011844A EC SP12011844 A ECSP12011844 A EC SP12011844A
Authority
EC
Ecuador
Prior art keywords
adenosina
phenoxi
metoxi
indeno
ona
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Jackson
Brian Christopher Shook
Aihua Wang
Mark Powell
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP12011844A publication Critical patent/ECSP12011844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con una nueva arilindenopirimidina, A, y sus usos terapéuticos y profilácticos. Los trastornos que se tratan y/o previenen incluyen la enfermedad de Parkinson.
ECSP12011844 2009-10-29 2012-04-27 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo ECSP12011844A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25592509P 2009-10-29 2009-10-29

Publications (1)

Publication Number Publication Date
ECSP12011844A true ECSP12011844A (es) 2012-06-29

Family

ID=43413792

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011844 ECSP12011844A (es) 2009-10-29 2012-04-27 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo

Country Status (12)

Country Link
US (1) US20110105540A1 (es)
KR (1) KR20120091242A (es)
CN (1) CN102612515A (es)
AU (1) AU2010313574A1 (es)
CA (1) CA2779091A1 (es)
CR (1) CR20120288A (es)
EA (1) EA201290239A1 (es)
EC (1) ECSP12011844A (es)
IL (1) IL219293A0 (es)
MX (1) MX2012004992A (es)
PH (1) PH12012500863A1 (es)
WO (1) WO2011053507A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
IL284745B2 (en) 2019-01-11 2025-08-01 Omeros Corp Compositions comprising gpr174 inhibitory compounds and uses thereof for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958328B2 (en) * 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
JP4725963B2 (ja) * 2003-10-03 2011-07-13 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド アリールインデノピリジンおよびアリールインデノピリミジンならびにアデノシンＡ２ａ受容体アンタゴニストとしてのそれらの使用
EP2217575A1 (en) * 2007-10-24 2010-08-18 Janssen Pharmaceutica, N.V. Arylindenopyrimidines and their use as adenosine a2a receptor antagonists
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a

Also Published As

Publication number Publication date
PH12012500863A1 (en) 2012-11-26
US20110105540A1 (en) 2011-05-05
CR20120288A (es) 2012-10-25
KR20120091242A (ko) 2012-08-17
CN102612515A (zh) 2012-07-25
CA2779091A1 (en) 2011-05-05
IL219293A0 (en) 2012-06-28
EA201290239A1 (ru) 2012-12-28
AU2010313574A1 (en) 2012-05-17
MX2012004992A (es) 2012-06-12
WO2011053507A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
PE20150641A1 (es) Antagonistas del receptor st2l y metodos de uso
ECSP11010932A (es) Compuestos de azaindazol como antagonistas del receptor de ccr1
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
UY33109A (es) Nuevos antagonistas del receptor CCR2 y usos de los mismos
CO6920295A2 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
UY30253A1 (es) Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
CL2013000933A1 (es) Compuestos derivados de furo[3,2-d]pirimidina y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una afeccion que esta mediada por la actividad de una proteina quinasa, tal como cancer, trastornos cardiovasculares, del snc e inmunes, y enfermedades relacionadas con la inmunodeficiencia adquirida.
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
CO6930360A2 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas preferentes del receptor de canabinoides 2
ECSP11010977A (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
MX383154B (es) Usos de naltrexona y bupoprion para tratar depresión mayor.
CU23899B1 (es) Benzotiazoles como moduladores del receptor de grelina
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
ECSP12011844A (es) 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
AR069026A1 (es) Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
ECSP12011841A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON HETEROCICLILO Y SU USO COMO ANTAGONISTAS DE LOS RECEPTORES DE ADENOSINA A2a ALTAMENTE SELECTIVOS
ECSP12011843A (es) Arilindenopirimidinas sustituidas con arilo y su uso como antagonistas de receptores de adenosina a2a altamente selectivos
CR20110258A (es) METILENAMINAS DE TIENO[2,3-d] PIRIMIDINA Y SU USO COMO ANTAGONISTA DE RECEPTORES DE ADENOSINA A2a
MX2010008103A (es) Metodo para optimizar el tratamiento de enfermedades proliferativas mediadas por el receptor de cinasa de tirosina kit con imatinib.